Back to the main directory
EarningsReview / Equity
- Biotage - Buy/SEK 200: Astrea saves the day, again by Nordea
- Graenges - Buy/SEK 155 (140): Solid report and exciting outlook by Nordea
- Neste - Buy/EUR 44 (49): Margin expectations turn heavily towards H2 2024 by Nordea
- Sparebank 1 SR-Bank - Hold: Decent momentum by Nordea
- Konecranes - Still more upside potential left by Danske Bank Equity Research
- Getinge - A DECENT QUARTER BUT A STILL OPAQUE OUTLOOK by Equita Sim
- A great fibre provider (& questions for mgmt..) by BNP Paribas Exane
- INVEST SECURITIES - AFFLUENT MEDICAL : Nouveau bridge de financement - ACHAT, OC 3,3€ vs 3,2€ by Invest Securities
- INVEST SECURITIES - VALBIOTIS : Résultats 2023 conformes, un newsflow à suivre - ACHAT, OC 9,6€ vs 10,1€ by Invest Securities
- STEF - Un trimestre qui reste dans le vert by MidCap Partners
- Ateme - CA T1 2024 by MidCap Partners
- Affluent Medical - Horizon de trésorerie étendu by MidCap Partners
- Groupe Guillin SA - De bons résultats mais sous nos attentes by MidCap Partners
- Groupe SEB - Nettement sous-estimé by MidCap Partners
- VINCI: VENTAS 1T’24 (ANÁLISIS BANCO SABADELL) by Sabadell
- INVEST SECURITIES - UNIBAIL-RODAMCO : Un trimestre sans surprise mais de qualité - ACHAT, OC 84€ by Invest Securities
- AIRBUS: RDOS. 1T’24 (ANÁLISIS BANCO SABADELL) by Sabadell
- Gentera (GENTERA* MM) by HSBC
- INVEST SECURITIES - DASSAULT SYSTEMES : Crédibilité écornée, confiance à restaurer - ACHAT, OC 50€ vs 48€ by Invest Securities
- SAFRAN: VENTAS 1T’24 (ANÁLISIS BANCO SABADELL) by Sabadell
- CELLNEX: 1Q’24 RESULTS (ANÁLISIS BANCO SABADELL) by Sabadell
- Affluent Medical - Extended Cash Horizon by MidCap Partners
- Remy Cointreau SA - Amélioration en T4 portée par le Cognac notamment en Chine mais les US restent en peine. by MidCap Partners
- Median Technologies - Dynamique commerciale confirmée by MidCap Partners
- Remy Cointreau SA - Q4 Improvement Driven by Cognac Particularly in China But the US IS Struggling by MidCap Partners